Genomics and Precision Health Database

Please Wait . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

---

Query Trace: Prenatal testing[orginal query]>>Evidence Synthesis[Product Type]

Publication
Psychological and social consequences of non-invasive prenatal testing (NIPT): a scoping review. Labonté Valérie et al. BMC pregnancy and childbirth 2019 Oct 19(1) 385 Similar articles in PubMed
Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review. Kessels Sharon J M et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Aug Similar articles in PubMed
CLINGEN Actionability Report for Familial Adenomatous Polyposis - APC ClinGen Actionability Working Group
CLINGEN Actionability Report for Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A) - F5 ClinGen Actionability Working Group
CLINGEN Actionability Report for Hereditary Hemorrhagic Telangiectasia - ENG, ACVRL1, SMAD4, GDF2 ClinGen Actionability Working Group
CLINGEN Actionability Report for Phenylketonuria (PKU) - PAH ClinGen Actionability Working Group
CLINGEN Actionability Report for Malignant Hyperthermia Susceptibility - RYR1, CACNA1S ClinGen Actionability Working Group
CLINGEN Actionability Report for MUTYH-Associated Polyposis - MUTYH ClinGen Actionability Working Group
CLINGEN Actionability Report for Basal Cell Nevus Syndrome (BCNS) - PTCH1 ClinGen Actionability Working Group
CLINGEN Actionability Report for Multiple Endocrine Neoplasia Type I - MEN1 ClinGen Actionability Working Group
CLINGEN Actionability Report for Hypophosphatemic rickets, autosomal dominant-FGF23 ClinGen Actionability Working Group
CLINGEN Actionability Report for Acrodermatitis enteropathica, zinc-deficiency type-SLC39A4 ClinGen Actionability Working Group
CLINGEN Actionability Report for Homocystinuria due to Cystathionine Beta-Synthase Deficiency - CBS ClinGen Actionability Working Group
CLINGEN Actionability Report for Glycogen Storage Disease 2 - GAA ClinGen Actionability Working Group
CLINGEN Actionability Report for Wilms tumor-WT1 ClinGen Actionability Working Group
CLINGEN Actionability Report for Ehlers-Danlos syndrome, classic type - COL5A1, COL5A2 ClinGen Actionability Working Group
CLINGEN Actionability Report for Pancreatic cancer/melanoma syndrome - CDKN2A ClinGen Actionability Working Group
CLINGEN Actionability Report for Multiple Endocrine Neoplasia IIA, Familial Medullary Thyroid Cancer - RET ClinGen Actionability Working Group
CLINGEN Actionability Report for Juvenile polyposis syndrome - SMAD4, BMPR1A ClinGen Actionability Working Group
CLINGEN Actionability Report for Homozygous Familial Hypercholesterolemia - LDLR, APOB, PCSK9 ClinGen Actionability Working Group
CLINGEN Actionability Report for Familial Hypertrophic Cardiomyopathy - ACTC1, CSRP3, MYBPC3, MYH7, MYL2, MYL3, PRKAG2, TNNI3, TNNT2, TPM1 ClinGen Actionability Working Group
CLINGEN Actionability Report for DICER1-Related Disorders-DICER1 ClinGen Actionability Working Group
CLINGEN Actionability Report for Hemochromatosis, Type 1-HFE ClinGen Actionability Working Group
CLINGEN Actionability Report for Brugada Syndrome - SCN5A ClinGen Actionability Working Group
CLINGEN Actionability Report for Autosomal Dominant Polycystic Kidney Disease - DNAJB11, GANAB, PKD1, PKD2 ClinGen Actionability Working Group
CLINGEN Actionability Report for Catecholaminergic Polymorphic Ventricular Tachycardia - RYR2 ClinGen Actionability Working Group
CLINGEN Actionability Report for Wilson Disease - ATP7B ClinGen Actionability Working Group
CLINGEN Actionability Report for Neurofibromatosis Type II -NF2 ClinGen Actionability Working Group
CLINGEN Actionability Report for Hereditary Leiomyomatosis and Renal Cell Cancer - FH ClinGen Actionability Working Group
CLINGEN Actionability Report for Hypophosphatemic rickets, X-linked dominant-PHEX ClinGen Actionability Working Group
CLINGEN Actionability Report for Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukocenphalopathy, type 1 - NOTCH3 ClinGen Actionability Working Group
CLINGEN Actionability Report for Familial Mediterranean Fever (AR) - MEFV ClinGen Actionability Working Group
CLINGEN Actionability Report for Familial Mediterranean Fever (AD) - MEFV ClinGen Actionability Working Group
CLINGEN Actionability Report for Gaucher Disease - GBA ClinGen Actionability Working Group
CLINGEN Actionability Report for Ornithine Transcarbamylase Deficiency-OTC ClinGen Actionability Working Group
CLINGEN Actionability Report for Lynch Syndrome - MLH1, MSH2, MSH6, PMS2, EPCAM ClinGen Actionability Working Group
CLINGEN Actionability Report for Loeys-Dietz Syndrome - SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2 ClinGen Actionability Working Group
The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis. Prefumo Federico et al. PloS one 2019 14(6) e0218166 Similar articles in PubMed
Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China. Xu Yan et al. International journal of technology assessment in health care 2019 May 1-6 Similar articles in PubMed
The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis. Bayón J C et al. Cost effectiveness and resource allocation : C/E 2019 176 Similar articles in PubMed
Perspectives of Pregnant People and Clinicians on Noninvasive Prenatal Testing: A Systematic Review and Qualitative Meta-synthesis. et al. Ontario health technology assessment series 2019 19(5) 1-38 Similar articles in PubMed
Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment. et al. Ontario health technology assessment series 2019 19(4) 1-166 Similar articles in PubMed
Facilitating informed choice about non-invasive prenatal testing (NIPT): a systematic review and qualitative meta-synthesis of women's experiences. Cernat Alexandra et al. BMC pregnancy and childbirth 2019 Jan 19(1) 27 Similar articles in PubMed
Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. Kostenko Emilia et al. Fetal diagnosis and therapy 2018 Aug 1-11 Similar articles in PubMed
High-throughput, non-invasive prenatal testing for fetal RHD genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. Saramago Pedro et al. BJOG : an international journal of obstetrics and gynaecology 2018 Feb Similar articles in PubMed
Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Badeau Mylène et al. The Cochrane database of systematic reviews 2017 Nov 11CD011767 Similar articles in PubMed
Has non-invasive prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome? Hill Melissa et al. Prenatal diagnosis 2017 Nov Similar articles in PubMed
Cell-free DNA noninvasive prenatal screening for aneuploidy versus conventional screening: a systematic review of economic evaluations. Nshimyumukiza L et al. Clinical genetics 2017 Oct Similar articles in PubMed
Woman's Pre-Conception Evaluation: Genetic and Fetal Risk Considerations for Counselling and Informed Choice. Wilson R Douglas et al. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2017 Oct Similar articles in PubMed
Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and meta-analysis. Iwarsson Erik et al. Acta obstetricia et gynecologica Scandinavica 2017 Jan 96(1) 7-18 Similar articles in PubMed
Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating non-invasive prenatal testing. Maxwell Susannah et al. The Australian & New Zealand journal of obstetrics & gynaecology 2017 Mar Similar articles in PubMed
Contingent non-invasive prenatal testing: An opportunity to improve non-genetic aspects of fetal aneuploidy screening. Gyselaers Wilfried et al. Prenatal diagnosis 2015 Oct Similar articles in PubMed
Decision aids that support decisions about prenatal testing for Down syndrome: an environmental scan. Leiva Portocarrero Maria Esther et al. BMC medical informatics and decision making 15(1) 76 Similar articles in PubMed
Prenatal Testing in the Genomic Age: Clinical Outcomes, Quality of Life, and Costs. Kaimal Anjali J et al. Obstet Gynecol 2015 Sep 3. Similar articles in PubMed
Advantages and Disadvantages of Different Implementation Strategies of Non-Invasive Prenatal Testing in Down Syndrome Screening Programmes. Mersy Elke et al. Public Health Genomics 2015 Jul 18. Similar articles in PubMed
An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population. Benn Peter et al. PLoS ONE 2015 10(7) e0132313 Similar articles in PubMed
Technical Update: Preimplantation Genetic Diagnosis and Screening. Dahdouh Elias M et al. J Obstet Gynaecol Can 2015 May 37(5) 451-63 Similar articles in PubMed
A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States. Walker Brandon S et al. PLoS ONE 2015 10(7) e0131402 Similar articles in PubMed
Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. Fairbrother Genevieve et al. J. Matern. Fetal. Neonatal. Med. 2015 May 22. 1-5 Similar articles in PubMed
Non-invasive Prenatal Testing: A Review of the Cost Effectiveness and Guidelines Similar articles in PubMed
Noninvasive Prenatal Testing for Trisomy 21, 18 and 13 - Clinical Experience from 146,958 Pregnancies. Similar articles in PubMed
The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Similar articles in PubMed
A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. Similar articles in PubMed